Paying users zone. Data is hidden behind .
Get 1-month access to Allergan PLC for $15.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Allergan PLC (AGN)
Enterprise Value to EBITDA (EV/EBITDA)
Intermediate level
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Allergan PLC, EBITDA calculation
US$ in thousands
Based on: 10-K (filing date: 2019-02-15), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18).
Item | Description | The company |
---|---|---|
EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Allergan PLC’s EBITDA decreased from 2016 to 2017 but then slightly increased from 2017 to 2018. |
Enterprise Value to EBITDA Ratio, Current
Allergan PLC, current EV/EBITDA calculation, comparison to benchmarks
Selected Financial Data (US$ in thousands) | |
Enterprise value (EV) | ![]() |
Earnings before interest, tax, depreciation and amortization (EBITDA) | ![]() |
Valuation Ratio | |
EV/EBITDA | ![]() |
Benchmarks | |
EV/EBITDA, Competitors1 | |
Abbott Laboratories | ![]() |
AbbVie Inc. | ![]() |
Amgen Inc. | ![]() |
Biogen Inc. | ![]() |
Bristol-Myers Squibb Co. | ![]() |
Eli Lilly & Co. | ![]() |
Gilead Sciences Inc. | ![]() |
Johnson & Johnson | ![]() |
Merck & Co. Inc. | ![]() |
Pfizer Inc. | ![]() |
Regeneron Pharmaceuticals Inc. | ![]() |
EV/EBITDA, Sector | |
Pharmaceuticals & Biotechnology | ![]() |
EV/EBITDA, Industry | |
Health Care | ![]() |
Based on: 10-K (filing date: 2019-02-15).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Allergan PLC, historical EV/EBITDA calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Enterprise value (EV)1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Earnings before interest, tax, depreciation and amortization (EBITDA)2 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Valuation Ratio | ||||||
EV/EBITDA3 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
EV/EBITDA, Competitors4 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Bristol-Myers Squibb Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
EV/EBITDA, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
EV/EBITDA, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-15), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18).
3 2018 Calculation
EV/EBITDA = EV ÷ EBITDA
= ÷
=
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Allergan PLC’s EV/EBITDA ratio decreased from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level. |